New CAR T-Cell combo shows promise for tough lymphoma

NCT ID NCT01840566

First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 26 times

Summary

This early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seventeen adults with relapsed or refractory disease, including diffuse large B-cell lymphoma, are enrolled. The main goal is to find the safest dose of these CAR T-cells and monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Limited protocol activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited protocol activites)

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.